Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LP12 + OVA8 + CpG + LLP2A
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
LP12 + OVA8 + CpG + LLP2A is an experimental, programmable peptide nucleic acid (PNA)-based nanovaccine (PVN) designed for anticancer immune activation. The platform utilizes an 11-mer PNA scaffold (LP12) that facilitates the precise, "one-pot" assembly of multiple functional moieties via complementary PNA strand hybridization. This specific formulation incorporates three key components: an ovalbumin-derived antigenic peptide (OVA8, specifically the SIINFEKL epitope), a CpG oligonucleotide adjuvant, and an LLP2A ligand. The LLP2A ligand is designed to target activated α4β1 integrin (also known as VLA-4), which is expressed on both immune cells (such as dendritic cells) and certain tumor cells like melanoma. By targeting these cells, the vaccine enhances antigen presentation and stimulates a robust immune response involving CD8+ T cells and natural killer (NK) cells. In preclinical studies, this nanovaccine has demonstrated the ability to cause significant tumor regression and improve survival in syngeneic melanoma models.
- Other names
- PNA-based vaccine nanoplatformPVN-OVA8-CpG-LLP2APVN-OVA-8-CpG-LLP2APVN-OVA 8-CpG-LLP2ALP11[OVA8/CpG/LLP2A]LP10[OVA8/CpG/LLP2A]
02
Targets
TLR9 (Toll-like receptor 9)α4β1 (Integrin α4β1)MHC I (MHC class I})
Beyond the preview
Go deeper on LP12 + OVA8 + CpG + LLP2A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LP12 + OVA8 + CpG + LLP2A.